share_log
Benzinga ·  May 2 08:33
60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment